Application of GSK3beta inhibitor and / or HRR inhibitor in preparation of medicine for treating FHIT deletion type lung cancer

By inhibiting the GSK3β and HRR pathways, using GSK3β inhibitors and HRR inhibitors, the problem of insufficient targets for FHIT-deficient lung cancer treatment is solved, effective inhibition of FHIT-deficient lung cancer cells is achieved, and new treatment ideas are provided.

CN118903437APending Publication Date: 2024-11-08UNIV OF MACAU
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411058434.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

At present, targeted treatment of lung cancer is mainly focused on limited targets, and it is not effective in treating FHIT-deletion lung cancer, and there is a lack of broad-spectrum drug targets.

Method used

By discovering the GSK3β and HRR pathways as synthetic lethal targets for FHIT-deletion lung cancer, GSK3β inhibitors and HRR inhibitors were used to inhibit the growth of FHIT-deletion lung cancer cells, including siRNA, small molecule compounds and ATR inhibitors.

Benefits of technology

Inhibitors of GSK3β and HRR pathways selectively inhibit the growth of FHIT-deletion lung cancer cells, leading to activation of DNA damage repair pathways and apoptosis, providing new targets for the treatment of FHIT-deletion lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004977098010000011
    Figure HDA0004977098010000011
  • Figure HDA0004977098010000012
    Figure HDA0004977098010000012
  • Figure HDA0004977098010000021
    Figure HDA0004977098010000021
Patent Text Reader

Abstract

The invention discloses an application of a GSK3beta inhibitor and / or an HRR inhibitor in preparation of a medicine for treating FHIT deletion type lung cancer. According to the invention, the glycogen synthase kinase 3beta (GSK3beta) and homologous recombinant DNA repair (HRR) pathway is found to be a synthesis lethal target of FHIT in lung cancer for the first time; the FHIT-deficient lung cancer cell line can inhibit a GSK3beta or HRR pathway, comprises an ATR / BRCA1 / RAD51 axis, and can significantly inhibit DNA double-chain breakage repair in FHIT-deficient lung cancer cells, resulting in DNA damage accumulation and cell apoptosis; and a basis is provided for taking GSK3beta and HRR pathways as feasible drug targets for the FHIT deletion type lung cancer. Moreover, the application further studies that in the non-FHIT-deficient lung cancer, simultaneous inhibition of FHIT and GSK3beta / HRR still can cause synthesis lethal of cells, and the application direction is further expanded.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of a GSK3β inhibitor and / or an HRR inhibitor in the preparation of a drug for treating FHIT-deficient lung cancer. Background Art

[0002] Lung cancer is one of the most common primary malignant tumors and the leading cause of cancer death. [1] . Despite great progress in cancer research and treatment, the mortality rate of lung cancer remains the highest among all cancers. Current targeted therapies for lung cancer mainly focus on oncogene drug targets, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), murine sarcoma viral oncogene (KRAS), murine sarcoma viral oncogene homolog B1 (BRAF), mesenchymal-epithelial transition factor (MET) and phosphatidylinositol 3-kinase p110a subunit (PIK3CA), which are applicable to 30%-40% of lung cancers. [2-5] The remaining lung cancer patients cannot benefit from current oncogene-directed targeted therapies due to the lack of actionable targets. Therefore, it is very important to identify and develop new drug targets that can be widely applicable to lung cancer patients for whom currently no targeted treatment options are available.

[0003] Smoking is the number one risk factor for lung cancer. More than 90% of lung cancer cases in men and more than 80% of lung cancer cases in women worldwide can be attributed to smoking. [6] It is well known that tobacco smoke releases at least 70 known chemical carcinogens, such as N-nitrosamines, aromatic amines and benzene, which can cause DNA damage. In the genome, there is a region called a "fragile site", which is a part of the genome that is highly sensitive to DNA damaging factors. Tobacco smoke mainly damages a fragile site in the genome, namely FRA3B located on chromosome 3p14.2. [7] Molecular characterization of the FRA3B fragile site revealed that the site contains the tumor suppressor FHIT (fragile histidine triad). Loss of FHIT is frequently observed in most cancers, especially in lung cancer, which accounts for more than 80% of lung cancer cases. [8] In addition, the FHIT deletion rate in smoker tumors (75%) was significantly higher than that in non-smoker tumors (39%). [9] Mice with heterozygous or homozygous deletion of Fhit show increased tumor susceptibility

[10] Transferring the FHIT gene to Fhit+ / - mice significantly inhibited the occurrence of chemical carcinogen-induced tumors.

[11] FHIT deficiency is associated with reduced apoptosis

[12] , is associated with increased EMT and metastatic potential and confers chemoresistance to tumors [13-15]Furthermore, restoring FHIT expression induced apoptosis and inhibited tumorigenicity in lung, cervical, and breast cancer models. [16,17] Together, these observations provide clear evidence that FHIT is a tumor suppressor that regulates the tumorigenic and metastatic potential of lung cancer.

[0004] Because FHIT deficiency is frequently associated with lung cancer in smokers, exploiting FHIT deficiency may provide an opportunity to develop broad-spectrum drug targets for lung cancer patients for whom no manipulable cancer-promoting factors have yet to be identified.

[0005] Synthetic lethality is a promising approach to target tumor suppressor mutations with pharmacological agents. The successful clinical introduction of PARP (poly (ADP-ribose) polymerase) inhibitors for the treatment of breast and ovarian cancers with tumor suppressor BRCA mutations has well demonstrated the effectiveness of synthetic lethality in treating cancer.

[18] To this end, we searched for synthetic lethal targets of FHIT to discover viable targets for the treatment of FHIT-deficient lung cancer.

[0006] References

[0007] 1.Sung,H.,et al.,Global Cancer Statistics 2020:GLOBOCAN Estimates ofIncidence and Mortality Worldwide for 36Cancers in 185Countries.CA:a CancerJournal For Clinicians,2021.71(3):p.209-249.

[0008] 2.Blair,HA,Sotorasib:First Approval.Drugs,2021.81(13):p.1573-1579.

[0009] 3. Peters, S., et al., Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 2017.377(9):p.829-838.

[0010] 4.Maemondo,M.,et al.,Gefitinib or chemotherapy for non-small-celllung cancer with mutated EGFR.N Engl J Med,2010.362(25):p.2380-8.

[0011] 5.Alamgeer,M.,V.Ganju,and D.N.Watkins,Novel therapeutic targets innon-small cell lung cancer.Current Opinion In Pharmacology,2013.13(3):p.394-401.

[0012] 6.Proctor,R.N.,Tobacco and the global lung cancer epidemic.NatureReviews.Cancer,2001.1(1):p.82-86.

[0013] 7.Huebner,K.and C.M.Croce,FRA3B and other common fragile sites:theweakest links.Nature Reviews.Cancer,2001.1(3):p.214-221.

[0014] 8.Pekarsky,Y.,et al.,FHIT:from gene discovery to cancer treatment andprevention.The Lancet.Oncology,2002.3(12):p.748-754.

[0015] 9.Sozzi,G.,et al.,Loss of FHIT function in lung cancer andpreinvasive bronchial lesions.Cancer Research,1998.58(22):p.5032-5037.

[0016] 10.Zanesi,N.,et al.,The tumor spectrumin FHIT-deficientmice.Proceedings of the National Academy of Sciences of the United States ofAmerica,2001.98(18):p.10250-10255.

[0017] 11.Zanesi,N.,Y.Pekarsky,and C.M.Croce,Amouse model of the fragilegene FHIT:From carcinogenesis to gene therapy and cancer prevention.MutationResearch,2005.591(1-2):p.103-109.

[0018] 12.Sard,L.,et al.,The tumor-suppressor gene FHIT is involved in theregulation of apoptosis and in cell cycle control.Proceedings of the NationalAcademy ofSciences of the United States of America,1999.96(15):p.8489-8492.

[0019] 13.Joannes,A.,et al.,Fhit regulates EMT targets through an EGFR / Src / ERK / Slug signaling axis in human bronchial cells.Molecular Cancer Research:MCR,2014.12(5):p.775-783.

[0020] 14.Suh,S.S.,et al.,FHIT suppresses epithelial-mesenchymal transition(EMT)and metastasis in lung cancer through modulation of microRNAs.PLoSGenet,2014.10(10):p.e1004652.

[0021] 15.Ottey,M.,et al.,Fhit-deficient normal and cancer cells aremitomycin C and UVC resistant.British Journal of Cancer,2004.91(9):p.1669-1677.

[0022] 16.Roz,L.,et al.,Restoration of fragile histidine triad(FHIT)expression induces apoptosis and suppresses tumorigenicity in lung andcervical cancer cell lines.Proc Natl Acad Sci U S A,2002.99(6):p.3615-20.

[0023] 17.Khedri,A.,et al.,Signaling Crosstalk of FHIT,p53,and p38 inetoposide-induced apoptosis in MCF-7cells.Journal of Cellular Biochemistry,2019.120(6):p.9125-9137.

[0024] 18.Farmer,H.,et al.,Targeting the DNArepair defect in BRCAmutantcells as atherapeutic strategy.Nature,2005.434(7035):p.917-921.

[0025] 19. C.S.,et al.,The cell-cycle checkpoint kinase Chk1 isrequired for mammalian homologous recombination repair.Nature Cell Biology,2005.7(2):p.195-201.

[0026] 20.Ko, J.-C., et al., HSP90 inhibition induces cytotoxicity via down-regulation of Rad51expression and DNArepair capacity in non-small cell lungcancer cells. Regulatory Toxicology and Pharmacology: RTP, 2012.64(3):p.415-424.

[0027] 21. Stecklein, SR, et al., BRCA1 and HSP90 cooperate in homologous and non-homologous DNAdouble-strand-break repair and G2 / M checkpointactivation. Proceedings of the National Academy of Sciences of the United States of America, 2012.109(34):p.13650-13655. Summary of the invention

[0028] The purpose of the present invention is to discover the synthetic lethality between FHIT and GSK3β, and that HRR inhibitors play a major role in synthetic lethality, and to find that inhibiting GSK3β or HRR can be used as a feasible target for the treatment of FHIT-deficient lung cancer.

[0029] The technical solution adopted by the present invention is:

[0030] The first aspect of the present invention provides the use of a GSK3β inhibitor and / or an HRR inhibitor in the preparation of a medicament for treating FHIT-deficient lung cancer.

[0031] Preferably, the GSK3β inhibitor includes substances that inhibit GSK3β gene expression, silence or knock out GSK3β gene, and / or substances that inhibit GSK3β protein content and / or activity.

[0032] Preferably, the GSK3β inhibitor comprises at least one of shRNA, siRNA, dsRNA, sgRNA, miRNA, cDNA, antisense RNA / DNA, small molecule compounds, peptides, and antibodies.

[0033] Preferably, the sequence of the siRNA is:

[0034] Sense-5'-GAUACGUCAGUGGUCUAAAAUGCTA-3';

[0035] Antisense-5'-UAGCAUUUUAGACCACUGACGUAUCAA-3'.

[0036] Preferably, the small molecule compound includes CHIR99021, CP21R7, AR-A014418, Tideglusib, or a pharmaceutically acceptable salt thereof.

[0037] Preferably, the pharmaceutically acceptable salts include, but are not limited to, pharmaceutically acceptable acid addition salts, such as salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and salts of organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, diethanolamine, lysine or ethylenediamine.

[0038] Preferably, the HRR inhibitor comprises an ATR inhibitor.

[0039] Preferably, the ATR inhibitor, CHK1 inhibitor, HSP90 inhibitor include substances that inhibit the expression of ATR, CHK1, HSP90 genes, silence or knock out ATR, CHK1, HSP90 genes, and / or substances that inhibit the content and / or activity of ATR, CHK1, HSP90 proteins.

[0040] Preferably, the ATR inhibitor, CHK1 inhibitor, and HSP90 inhibitor include at least one of shRNA, siRNA, dsRNA, sgRNA, miRNA, cDNA, antisense RNA / DNA, small molecule compounds, peptides, and antibodies.

[0041] Preferably, the small molecule compound of the ATR inhibitor includes VE-821, AZD6738, M1774, ART0380, RP-3500, VE-822, SC0245, BAY1895344, ATRN-119, TQB3015, LF0397, ATG-018, HRS2398 or pharmaceutically acceptable salts thereof.

[0042] Preferably, the small molecule compound in the CHK1 inhibitor includes LY2603618, CHIR-124, SCH900776, GDC-0575 or pharmaceutically acceptable salts thereof.

[0043] Preferably, the small molecule compound in the HSP90 inhibitor includes geldanamycin, NVP-HSP990, 17-AAG, NVP-HSP990 or pharmaceutically acceptable salts thereof.

[0044] Preferably, the pharmaceutically acceptable salts include, but are not limited to, pharmaceutically acceptable acid addition salts, such as salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and salts of organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, diethanolamine, lysine or ethylenediamine.

[0045] Preferably, the inhibition of gene expression, silencing or knocking out of genes can be achieved by gene mutation, gene silencing, gene knockout, gene editing or gene knockdown techniques known to those skilled in the art. For example, RNA interference (RNAi) technology can be used to specifically eliminate or shut down the expression of specific genes; tools using gene editing technology can be CRISPR / Cas9 technology, zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs) technology, etc., but are not limited thereto.

[0046] The technology of inactivating gene expression or silencing gene at the post-transcriptional level or translational level by using gene knock-down technology is well known to those skilled in the art. The gene knock-down technology includes RNA interference, Morpholino interference, antisense nucleic acid, ribozyme or dominant negative inhibitory mutation but is not limited thereto.

[0047] Preferably, the administration of the drug includes oral administration, subcutaneous injection, intravenous injection, and intraperitoneal injection.

[0048] Preferably, the drug further comprises pharmaceutically acceptable excipients; preferably, the pharmaceutical excipients comprise one or more of diluents, fillers, excipients, excipients, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants and flavoring agents.

[0049] Preferably, the medicament contains an effective dose of a GSK3β inhibitor and / or a HRR inhibitor.

[0050] In the present invention, the appropriate daily dosage range of the GSK3β inhibitor is 1 ug-1 g / kg body weight; the above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment methods.

[0051] In the present invention, when the GSK3β inhibitor is administered to animals, the dosage of each administration is 10 mg-80 mg / kg mouse, and / or the administration period is 2 to 4 weeks.

[0052] In the present invention, the appropriate daily dosage range of the HRR inhibitor is 1 ug-1 g / kg body weight; the above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment methods.

[0053] The second aspect of the present invention provides a pharmaceutical composition comprising (1) and (2);

[0054] (1) GSK3β inhibitors and / or HRR inhibitors;

[0055] (2) FHIT inhibitors.

[0056] Preferably, the FHIT inhibitor includes a substance that inhibits FHIT gene expression, silences or knocks out FHIT gene, and / or a substance that inhibits FHIT protein content and / or activity.

[0057] Preferably, the FHIT inhibitor comprises at least one of shRNA, siRNA, dsRNA, sgRNA, miRNA, cDNA, antisense RNA / DNA, small molecule compounds, peptides, and antibodies.

[0058] Preferably, the sequence of the siRNA is:

[0059] Sense-5'-AUUCCAGCAAAAGAGCUAUUGCCAA-3'

[0060] Antisense-5'-UUGGCAAUAGCUCUUUUGCUGGAAUUC-3';

[0061] The sequence of the sgRNA includes:

[0062] sc-404220A:

[0063] Sense:AGGTCATGGAAGCGCTCCAC;

[0064] sc-404220B:

[0065] Sense:AACAAATCGGCCACTTCATC;

[0066] sc-404220C:

[0067] Sense:TTTCCTATTCACAAGAGCGA.

[0068] The third aspect of the present invention provides use of the pharmaceutical composition described in the second aspect of the present invention in the preparation of anti-lung cancer drugs.

[0069] The beneficial effects of the present invention are:

[0070] The present invention discovered for the first time that glycogen synthase kinase 3β (GSK3β) and homologous recombination DNA repair (HRR) pathways are synthetic lethal targets of FHIT in lung cancer. GSK3β and HRR pathway inhibitors selectively inhibit the growth of FHIT-deficient lung cancer tumors in vivo and in vitro. Its mechanism of action is that FHIT inactivation leads to activation of DNA damage repair pathways in lung cancer cells, especially HRR; inhibition of GSK3β or HRR pathways, including the ATR / BRCA1 / RAD51 axis, can significantly inhibit DNA double-strand break repair in FHIT-deficient lung cancer cells, leading to DNA damage accumulation and cell apoptosis. The present invention provides a basis for GSK3β and HRR pathways as feasible drug targets for FHIT-deficient lung cancer.

[0071] Moreover, the present application further studies that in non-FHIT-deficient lung cancer, simultaneous inhibition of FHIT and GSK3β / HRR still leads to synthetic cell lethality, which indicates that the simultaneous use of FHIT inhibitors and GSK3β / HRR inhibitors can be further used to prepare non-FHIT-deficient lung cancer drugs, further expanding the application direction. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figure 1 .Synthetic lethal drug screening. A: Construction of FHIT heterologous cell pairs (FHIT knockout cells FHIT - / - , upper figure; FHIT overexpressing cells OE , below); B: Schematic diagram of the screening process; C: Scatter plot of the Log10-IC50 data of drugs in the screening drug library, the colored data points represent the drug's effect on FHIT - / - The selectivity of HCC827 cells is more than 2 times higher than that of Parental HCC827 cells.

[0073] Figure 2 .GSK3β inhibitors have synthetic lethal effects on FHIT-deficient lung cancer cells in vitro. A and B are the effects of GSK3β inhibitor CHIR99021 on Parental and FHIT, respectively. - / - Effects of GSK3β inhibitor CHIR99021 on the viability of HCC827 cells; C and D are the effects of GSK3β inhibitor CHIR99021 on the viability of Parental (FHIT deficiency) and FHIT overexpression (FHIT OE ) Effects of GSK3β inhibitor CHIR99021 on the viability of Parental and FHIT cells- / - Effects of GSK3β inhibitor CHIR99021 on the clone formation of HCC827 cells; F: IncuCyte cell imaging system was used to detect the effects of GSK3β inhibitor CHIR99021 on Parental and FHIT - / - Effect of 24h3PO4 on the growth rate of HCC827 cells. *P<0.05, **P<0.01 (Student's t-test).

[0074] Figure 3 .Synthetic lethal interaction between FHIT and GSK3β. A and B show the effects of GSK3β inhibitor CHIR99021 on the viability of HCC827 cells treated with control siRNA and FHIT siRNA, respectively; C shows the effect of siRNA silencing on FHIT expression; D and E show the effects of GSK3β siRNA on Parental and FHIT, respectively. - / - Effects on HCC827 cell viability; F is to verify the effect of siRNA silencing on GSK3β expression. *P<0.05, **P<0.01 (Student's t-test).

[0075] Figure 4 .FHIT, GSK3β and DNA damage response. A: DNA damage marker γ-H2A.X in Parental and FHIT-deficient (FHIT - / - ) in HCC827 and H1650 cells; BD is the effect of GSK3β inhibitor CHIR99021 on Parental and FHIT - / - Effects of CHIR99021 on γ-H2A.X levels (B) and nuclear foci formation (CD) in HCC827 cells. E and F were evaluated by comet assay (single cell DNA gel electrophoresis assay) to evaluate the effects of CHIR99021 on Parental and FHIT - / - Effect of DNA damage on HCC827 cells. *P<0.05, **P<0.01 (Student's t-test).

[0076] Figure 5 .GSK3β inhibitor induces apoptosis in FHIT-deficient cells. A and B are the effects of GSK3β inhibitor CHIR99021 on Parental and FHIT cells, respectively. - / - Effects on HCC827 cell cycle; arrows indicate the increase in sub-G1 cell population; C and D are the effects of GSK3β inhibitor CHIR99021 on Parental and FHIT, respectively. - / -The effect of GSK3β inhibitor CHIR99021 on the apoptosis of HCC827 cells was detected by propidium iodide (PI) and cell apoptosis membrane marker Annexin V; E is the effect of GSK3β inhibitor CHIR99021 on Parental and FHIT - / - Effect of PARP cleavage (apoptosis marker) in HCC827 cells. *P<0.05, **P<0.01 (Student's t-test).

[0077] Figure 6 .FHIT, GSK3β and DNA double-strand break repair activity. A is the difference in DNA double-strand break repair activity between FHIT wild-type HCC827 cells and FHIT-deficient H460 cells analyzed by DNA damage repair reporter (DRR) system; HRR indicates homologous recombination repair, and NHEJ indicates non-homologous end joining; B is the difference in activity of DNA double-strand break repair pathway between FHIT wild-type (H1650 and HCC827) and FHIT-deficient (H460 and H1299) cells; C is the difference in activity of HCC827 or H1650 Parental and FHIT - / - The difference in activity of the DNA double-strand break repair pathway in cells. D and E show the effects of GSK3β inhibitor CHIR99021 on HRR (red) and NHEJ (green) activity, respectively. F shows the effects of GSK3β inhibitor CHIR99021 on Parental and FHIT - / - Effects of the activity of DNA double-strand break repair pathway in HCC827 cells. *P<0.05, **P<0.01 (Student's t-test).

[0078] Figure 7 .The DNA damage repair pathway is involved in the synthetic lethality of FHIT and GSK3β. A is the effect of ATR inhibitor VE-821 on HRR activity and the effect of DNA-PK inhibitor NU-7441 on NHEJ activity detected by DNA damage repair reporter (DDR) cells; BE are the effects of ATR inhibitor VE-821 (inhibiting HRR), DNA-PK inhibitor NU-7441 (inhibiting NHEJ), the combination of ATR inhibitor VE-821 and DNA-PK inhibitor NU-7441, and PARP inhibitor Olaparib (inhibiting DNA single-strand breaks) on Parental and FHIT. - / - Effects of GSK3β inhibitor CHIR99021 on the viability of HCC827 cells; F is the effect of GSK3β inhibitor CHIR99021 on Parental and FHIT - / - Effects of ATR phosphorylation in HCC827 cells; GH are the effects of ATR inhibitor VE-821 on Parental and FHIT - / -Effects of HRR pathway activity and DNA damage marker proteins in HCC827 cells.

[0079] Figure 8 .In vivo synthetic lethality of GSK3β inhibitors against FHIT-deficient lung cancer. AB are the effects of GSK3β inhibitor CHIR99021 on parental HCC827 tumors (A) or FHIT - / - Effects of GSK3β inhibitor CHIR99021 on the growth of HCC827 tumors (B). CD respectively show the effects of GSK3β inhibitor CHIR99021 on the growth of parerntal HCC827 tumors (C) or FHIT - / - Effect of GSK3β inhibitor CHIR99021 on the average wet weight of HCC827 tumor (D). Effect of GSK3β inhibitor CHIR99021 on the body weight of mice (FG). Effect of GSK3β inhibitor CHIR99021 on the levels of HRR pathway proteins (BRCA1 and RAD51), DNA damage markers (γ-H2A.X) and apoptosis markers (cleaved-caspase 3). **P<0.01 (Student's t-test). DETAILED DESCRIPTION

[0080] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0081] Example 1

[0082] To screen and identify synthetic lethal targets of FHIT in lung cancer, FHIT knockout (KO) and FHIT overexpression (OE) cell pairs were established in four lung cancer cell lines, including HCC827 (FHIT wild type), H1650 (FHIT wild type), H1299 (FHIT mutant), and H460 (FHIT mutant), using CRISPR / Cas9 gene editing and lentiviral overexpression systems.

[0083] The plasmids for constructing FHIT knockout cells were purchased from Sant cruz. The Fhit CRISPR / Cas9 KOPlasmid(h)pool includes three plasmids, each containing three sgRNAs, with the following sequences:

[0084] sc-404220A:

[0085] Sense:AGGTCATGGAAGCGCTCCAC(SEQ ID NO.1);

[0086] sc-404220B:

[0087] Sense:AACAAATCGGCCACTTCATC(SEQ ID NO.2);

[0088] sc-404220C:

[0089] Sense:TTTCCTATTCACAAGAGCGA(SEQ ID NO.3);

[0090] In addition, sc-404220-HDR plasmid A and sc-404220-HDR plasmid B plasmids were used as DNA repair templates after gene knockout. When constructing cells, Fhit CRISPR / Cas9 KO Plasmid (h) pool and c-404220-HDR plasmid were transfected into HCC827 or H1650 cells simultaneously.

[0091] FHIT overexpression cells were constructed by inserting FHIT cDNA (GeneID: 2272) into the pCDH-EF1-FHC plasmid to obtain the FHIT overexpression plasmid, which was then co-transfected with pCMV-dR8.2 dvpr and pCMV-VSVG into HEK-293T cells, packaged with FHIT overexpression lentivirus, and then infected with H460 or H1299 cells.

[0092] FHIT-KO in HCC827 and H1650 cells and FHIT-OE in H1299 and H460 cells were verified by Western blotting. Figure 1 A); then HCC827 FHIT isogenic cell pairs (parental FHIT wild-type and FHIT-KO cells, hereinafter referred to as Parental and FHIT - / - Cells) were screened for synthetic lethality in a highly selective inhibitor library (containing 318 specific small molecule inhibitors against various druggable targets of cells); each drug was serially diluted in a 384-well plate to prepare a total of 8 concentrations to obtain the specificity of each drug for Parental and FHIT - / - IC50 value of HCC827 cells ( Figure 1 B) Selective inhibition of FHIT - / - Four compounds (CHIR99021, LY2603618, SKI II, and NSC23766) were identified as synthetic lethal drug candidates for HCC827 cells ( Figure 1C). Among them, CHIR99021, a glycogen synthase kinase 3β (GSK3β) inhibitor, was ranked as the most important synthetic lethal compound.

[0093] Example 2

[0094] To further validate the screening results, the GSK3β inhibitor CHIR99021 was tested on HCC827 FHIT heterologous cell pairs ( Figure 2 AB) and H460 FHIT heterologous cell pairs ( Figure 2 GSK3β inhibitor CHIR99021 selectively inhibits the growth and clone formation of FHIT-deficient lung cancer cells ( Figure 2 AF).

[0095] To verify that the selective antiproliferative effect of CHIR99021 in FHIT-deficient lung cancer cells was due to the synthetic lethal interaction between FHIT and GSK3β rather than the off-target effect of the compound, specific siRNA was used to silence FHIT or GSK3β in lung cancer cells, and its synthetic lethal effect was analyzed;

[0096] FHIT siRNA:

[0097] Sense-5'-AUUCCAGCAAAAGAGCUAUUGCCAA-3' (SEQ ID NO.4);

[0098] Antisense-5'-UUGGCAAUAGCUCUUUUGCUGGAAUUC-3' (SEQ ID NO.5);

[0099] GSK3β siRNA:

[0100] Sense-5'-GAUACGUCAGUGGUCUAAAAUGCTA-3' (SEQ ID NO. 6);

[0101] Antisense-5'-UAGCAUUUUAGACCACUGACGUAUCAA-3' (SEQ ID NO.7);

[0102] The results showed that siRNA silencing of FHIT made HCC9827 cells sensitive to CHIR99021 treatment ( Figure 3 AC). On the other hand, siRNA silencing of GSK3β can induce FHIT - / - HCC827 cells are synthetically lethal (3D-F). These data indicate that GSK3β inhibition and FHIT deletion are synthetically lethal in lung cancer cells.

[0103] Example 3

[0104] FHIT is located at the FRA3B fragile site on chromosome 3 and is thought to be involved in DNA damage sensing. Therefore, this example analyzes the DNA damage response of lung cancer cells treated with a GSK3β inhibitor.

[0105] The results showed that with FHIT + / + Compared with cells, FHIT - / - HCC827 cells showed higher levels of the DNA damage marker γ-H2A.X ( Figure 4 A). GSK3β inhibitor further upregulated the level of γ-H2A.X and the formation of nuclear foci ( Figure 4 BD). In addition, GSK3β inhibitors significantly increased FHIT as assessed by comet assay. - / - DNA strand breaks in HCC827 cells, showing longer DNA tails (damaged DNA) ( Figure 4 EF).

[0106] To analyze the correlation between the DNA damage response and synthetic lethal cell death induced by GSK3β inhibitors, FHIT- allogeneic cells (Parental and FHIT) treated with CHIR99021 were examined. - / - The cell cycle and apoptosis of cells.

[0107] Flow cytometry analysis showed that CHIR99021 could significantly increase FHIT - / - Sub-G1 cell population in HCC827 cells ( Figure 5 AB) and Annexin V positive apoptotic cell population ( Figure 5 CD). In addition, CHIR99021 adds FHIT - / - Cleavage of PARP in HCC827 cells Figure 5 E), indicating that GSK3β inhibitors can selectively induce FHIT - / - HCC827 cells undergo apoptosis following increased DNA damage.

[0108] Example 4

[0109] To investigate the mechanism of DNA damage response activation in FHIT-deficient lung cancer cells, a DNA damage repair reporter (DRR) cell line was constructed using a reporter plasmid containing the I-SceI recognition sequence and GFP (for detecting NHEJ: non-homologous end joining) and mCherry (for detecting HRR: homologous recombination repair).

[0110] The results showed that compared with FHIT wild-type HCC827 cells, FHIT-deficient H460 cells showed significantly increased HRR activity and slightly higher NHEJ activity ( Figure 6 A).

[0111] Data from four lung cancer cells and two pairs of FHIT-heterogeneous cells also showed that FHIT-deficient lung cancer cells had higher HRR and NHEJ activities, as evidenced by increased levels of BRCA1 and RAD51 and increased levels of phosphorylated DNA-PKcs ( Figure 6 BC). GSK3β inhibitors can significantly inhibit the HRR and NHEJ activities of FHIT-deficient lung cancer cells ( Figure 6 DE), and inhibited the levels of BRCA1, RAD51, and phosphorylated DNA-PKcs ( Figure 6 F).

[0112] These results suggest that FHIT-deficient cells have increased DNA damage stress, thus activating DNA double-strand break repair activity to relieve DNA damage stress. Inhibition of GSK3β inhibits the DNA double-strand break repair system in FHIT-deficient cells, causing a large accumulation of DNA damage, overwhelming the cell's DNA damage repair capacity, and inducing cell death.

[0113] Example 5

[0114] To further demonstrate the concept of Example 4, HRR inhibitors (ATR inhibitor VE-821) and NHEJ inhibitors (DNA-PK inhibitor NU-7441) were tested ( Figure 7 A) and DNA single-strand break repair inhibitors (PARP inhibitor Olaparib) on FHIT-deficient lung cancer cells. The HRR inhibitor VE-821 has the highest synthetic lethality rate against FHIT-deficient lung cancer cells ( Figure 7 B) The synthetic lethality of NHEJ inhibitors and PARP inhibitors is weak ( Figure 7 C and E). Compared with the use of HRR inhibitors alone, the combination of HRR inhibitors and NHEJ inhibitors did not further enhance the synthetic lethality ( Figure 7 D), suggesting that HRR inhibitors play a major role in synthetic lethality.

[0115] Checkpoint kinase 1 (CHK1) is also an important regulator of HRR

[19] In fact, the CHK1 inhibitor LY2603618 was identified as the second most lethal drug in early screening ( Figure 1 C) In addition, heat shock protein 90 (HSP90) is known to be involved in HRR by regulating BRCA1 and RAD51 protein levels[20,21] The HSP90 inhibitor geldanamycin can induce synthetic lethality in lung cancer cells with FHIT deficiency ( Figure 7 F).

[0116] These results suggest that the synthetic lethality of GSK3β inhibitors in FHIT-deficient cells is mediated by inhibition of HRR. In addition, ATR phosphorylation levels were increased in FHIT-deficient cells, and GSK3β inhibitors inhibited ATR phosphorylation in cells ( Figure 7 G). ATR inhibitor significantly reduced the levels of BRCA1 and RAD51, and upregulated the level of γ-H2A.X ( Figure 7 H). These results suggest that GSK3β inhibitors inhibit HRR via the ATR / BRCA1 / RAD51 axis.

[0117] Example 6

[0118] To investigate the in vivo antitumor effects of GSK3β inhibitors on FHIT-deficient lung cancer cells, Parental and FHIT - / - HCC827 cells were implanted into the axillae of athymic nude mice and treated with control and two doses of CHIR99021 (30 mg / kg and 60 mg / kg) every day for three consecutive weeks. Tumor volume and mouse body weight were measured every 3 days.

[0119] The results showed that CHIR99021 could not inhibit the growth of Parental HCC827 tumors, but CHIR99021 at both doses could significantly inhibit FHIT - / - Growth of HCC827 tumors ( Figure 8 AD). No obvious drug toxicity was observed based on body weight measurements ( Figure 8 E) Analysis of xenograft tumor samples showed that FHIT cells treated with CHIR99021 - / - In tumors, BRCA1 and RAD51 levels were decreased, and γ-H2A.X and cleaved-caspase 3 levels were increased ( Figure 8 FG). These results suggest that GSK3β inhibitors induce synthetic lethality in FHIT-deficient lung cancers in vivo by inhibiting HRR.

[0120] Synthetic lethal therapy is a pharmacologically targeted therapy for cancers with tumor suppressor mutations, and has been shown to be effective in the clinical setting of cancer treatment. This approach is particularly suitable for cancers without identified specific oncogene drivers or manipulable targets. The use of GSK3β inhibitors and HRR pathway inhibitors for synthetic lethal targeting of FHIT loss in lung cancer cells provides new ideas for the development of targeted therapies and precision medicines for lung cancer and other types of cancers with high frequency of FHIT mutations. There are currently many experimental and clinical drugs targeting GSK3β or the HRR pathway, including but not limited to ATR inhibitors, CHK1 inhibitors, and HSP90 inhibitors. Drug combinations containing GSK3β inhibitors or HRR pathway inhibitors will be promising in the treatment of lung cancer or other types of cancers with FHIT loss.

[0121] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. Use of GSK3β inhibitors and / or HRR inhibitors in the preparation of drugs for treating FHIT-deficient lung cancer.

2. The use according to claim 1, characterized in that: The HRR inhibitor includes an ATR inhibitor, a CHK1 inhibitor and / or an HSP90 inhibitor.

3. The use according to claim 1 or 2, characterized in that: The GSK3β inhibitor, ATR inhibitor, CHK1 inhibitor, and HSP90 inhibitor respectively include substances that inhibit the expression of GSK3β, ATR, CHK1, and HSP90 genes, silence or knock out GSK3β, ATR, CHK1, and HSP90 genes, and / or substances that inhibit the content and / or activity of GSK3β, ATR, CHK1, and HSP90 proteins; preferably, the GSK3β inhibitor, ATR inhibitor, CHK1 inhibitor, and HSP90 inhibitor include at least one of shRNA, siRNA, dsRNA, sgRNA, miRNA, cDNA, antisense RNA / DNA, small molecule compounds, peptides, and antibodies.

4. The use according to claim 3, characterized in that: The small molecule compound in the GSK3β inhibitor includes CHIR99021, CP21R7, AR-A014418, Tideglusib or a pharmaceutically acceptable salt thereof; preferably, the sequence of the siRNA in the GSK3β inhibitor is: Sense-5'-GAUACGUCAGUGGUCUAAAAUGCTA-3'; Antisense-5'-UAGCAUUUUAGACCACUGACGUAUCAA-3'.

5. The use according to claim 3, characterized in that: The small molecule compounds in the ATR inhibitors include VE-821, AZD6738, M1774, ART0380, RP-3500, VE-822, SC0245, BAY1895344, ATRN-119, TQB3015, LF0397, ATG-018, HRS2398 or pharmaceutically acceptable salts thereof.

6. The use according to claim 3, characterized in that: The small molecule compounds in the CHK1 inhibitor include LY2603618, CHIR-124, SCH900776, GDC-0575 or pharmaceutically acceptable salts thereof; preferably, the small molecule compounds in the HSP90 inhibitor include geldanamycin, NVP-HSP990, 17-AAG, NVP-HSP990 or pharmaceutically acceptable salts thereof.

7. A pharmaceutical composition comprising (1) and (2); (1) The GSK3β inhibitor and / or HRR inhibitor according to any one of claims 1 to 6; (2) FHIT inhibitors.

8. The composition according to claim 7, characterized in that The FHIT inhibitor includes a substance that inhibits FHIT gene expression, silences or knocks out FHIT gene, and / or a substance that inhibits FHIT protein content and / or activity; preferably, the FHIT inhibitor includes at least one of shRNA, siRNA, dsRNA, sgRNA, miRNA, cDNA, antisense RNA / DNA, small molecule compounds, peptides, and antibodies; Preferably, the sequence of the siRNA is: Sense-5'-AUUCCAGCAAAAGAGCUAUUGCCAA-3'; Antisense-5'-UUGGCAAUAGCUCUUUUGCUGGAAUUC-3'.

9. Use of the pharmaceutical composition according to claim 7 or 8 in the preparation of a drug for treating lung cancer.

10. The use according to any one of claims 1 to 6 or claim 9, characterized in that: The administration methods of the drug include oral administration, subcutaneous injection, intravenous injection, and intraperitoneal injection; preferably, the drug also includes pharmaceutically acceptable excipients; preferably, the pharmaceutical excipients include one or more of diluents, fillers, excipients, excipients, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants and flavoring agents.

Citation Information

Cited By

  • Application of ATR / Chk1 signal channel inhibitor in promoting erythrocyte denucleation

    CN119746077A